Mark X. Sliwkowski
#154,254
Most Influential Person Now
Mark X. Sliwkowski's AcademicInfluence.com Rankings
Mark X. Sliwkowskibiology Degrees
Biology
#11764
World Rank
#15187
Historical Rank
Molecular Biology
#1847
World Rank
#1876
Historical Rank
Neuroscience
#1936
World Rank
#1992
Historical Rank
Biochemistry
#1959
World Rank
#2100
Historical Rank

Download Badge
Biology
Mark X. Sliwkowski's Degrees
- PhD Biochemistry University of California, Berkeley
- Bachelors Biochemistry University of California, Davis
Why Is Mark X. Sliwkowski Influential?
(Suggest an Edit or Addition)Mark X. Sliwkowski's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Untangling the ErbB signalling network (2001) (6547)
- Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. (2008) (1387)
- Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor* (2002) (1051)
- Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. (2004) (1043)
- Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index (2008) (1034)
- Identification of Heregulin, a Specific Activator of p185erbB2 (1992) (982)
- An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. (2003) (930)
- Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. (2002) (884)
- Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. (2009) (793)
- Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates (2012) (789)
- Treatment of HER2-positive breast cancer: current status and future perspectives (2012) (767)
- Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). (1999) (720)
- Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers (1999) (710)
- Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. (1994) (667)
- HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. (1995) (664)
- A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. (2008) (623)
- Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. (2010) (537)
- Antibody Therapeutics in Cancer (2013) (483)
- Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. (2004) (469)
- Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. (1993) (461)
- Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer (2011) (452)
- Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2–Positive Cancer (2011) (399)
- Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. (2005) (398)
- Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. (2006) (388)
- Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. (2000) (387)
- Neuregulin-3 (NRG3): a novel neural tissue-enriched protein that binds and activates ErbB4. (1997) (384)
- Binding specificities and affinities of egf domains for ErbB receptors (1999) (376)
- The erbB3 gene product is a receptor for heregulin. (1994) (353)
- Oncogenic ERBB3 mutations in human cancers. (2013) (328)
- A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. (2011) (306)
- Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab (2006) (291)
- Axon-induced mitogenesis of human Schwann cells involves heregulin and p185erbB2. (1995) (280)
- The influence of heregulins on human Schwann cell proliferation (1995) (255)
- Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer (2010) (242)
- Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer. (2010) (214)
- Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. (2001) (198)
- Identification of Gas6 as a growth factor for human Schwann cells (1996) (188)
- Overexpression of HER2/neu in solid tumours: an immunohistochemical survey (2001) (174)
- Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation. (2013) (163)
- Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy (2013) (159)
- Growth regulation of human breast and ovarian tumor cells by heregulin: Evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness. (1996) (155)
- Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells (1999) (152)
- CD20: a gene in search of a function. (2000) (150)
- Regulation of the acetylcholine receptor ϵ subunit gene by recombinant ARIA: An in vitro model for transynaptic gene regulation (1995) (125)
- Genetically engineered proinsulin constitutively processed and secreted as mature, active insulin. (1994) (125)
- Potential Mechanisms for Thrombocytopenia Development with Trastuzumab Emtansine (T-DM1) (2014) (124)
- Suppression of HER2/HER3-Mediated Growth of Breast Cancer Cells with Combinations of GDC-0941 PI3K Inhibitor, Trastuzumab, and Pertuzumab (2009) (124)
- Blockade of Epidermal Growth Factor- or Heregulin-Dependent ErbB2 Activation with the Anti-ErbB2 Monoclonal Antibody 2C4 Has Divergent Downstream Signaling and Growth Effects (2004) (107)
- Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice (2010) (106)
- Effects of Anti-VEGF on Pharmacokinetics, Biodistribution, and Tumor Penetration of Trastuzumab in a Preclinical Breast Cancer Model (2012) (103)
- Analysis of Fcγ Receptor IIIa and IIa Polymorphisms: Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients (2012) (102)
- γ-Heregulin: a novel heregulin isoform that is an autocrine growth factor for the human breast cancer cell line, MDA-MB-175 (1997) (99)
- A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4. (2001) (97)
- Preclinical studies with Erlotinib (Tarceva). (2003) (97)
- Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells (2018) (92)
- Trastuzumab emtansine (T-DM1): a novel agent for targeting HER2+ breast cancer. (2011) (92)
- Biological response to ErbB ligands in nontransformed cell lines correlates with a specific pattern of receptor expression. (1998) (89)
- Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering. (2014) (80)
- Identification of a Region within the ErbB2/HER2 Intracellular Domain That Is Necessary for Ligand-independent Association* (2002) (76)
- Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. (2010) (71)
- Association of Csk-homologous Kinase (CHK) (formerly MATK) with HER-2/ErbB-2 in Breast Cancer Cells* (1997) (70)
- Perspectives on Anti-HER Monoclonal Antibodies (2002) (69)
- Neuregulin-1 and human epidermal growth factor receptors 2 and 3 play a role in human lung development in vitro. (2000) (68)
- Suppression of breast cancer cell growth by a monoclonal antibody targeting cleavable ErbB4 isoforms (2009) (66)
- Cathepsin B Is Dispensable for Cellular Processing of Cathepsin B-Cleavable Antibody-Drug Conjugates. (2017) (65)
- Formation of a high affinity heregulin binding site using the soluble extracellular domains of ErbB2 with ErbB3 or ErbB4 (1998) (64)
- High-resolution solution structure of the EGF-like domain of heregulin-alpha. (1996) (59)
- Heregulin is rapidly translocated to the nucleus and its transport is correlated with c-myc induction in breast cancer cells. (1996) (59)
- Afucosylated Antibodies Increase Activation of FcγRIIIa-Dependent Signaling Components to Intensify Processes Promoting ADCC (2014) (57)
- Binding Interaction of the Heregulinβ egf Domain with ErbB3 and ErbB4 Receptors Assessed by Alanine Scanning Mutagenesis* (1998) (56)
- High cell-surface density of HER2 deforms cell membranes (2016) (55)
- Design, Construction, and In Vitro Analyses of Multivalent Antibodies (2003) (54)
- Heregulin enhances regenerative proliferation in postnatal rat utricular sensory epithelium after ototoxic damage (1999) (53)
- PPM1H is a p27 phosphatase implicated in trastuzumab resistance. (2011) (52)
- Incorporation and distribution of selenium into thiolase from Clostridium kluyveri. (1985) (47)
- Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer. (2014) (47)
- A potential role for activated HER-2 in prostate cancer. (2000) (46)
- Ready to partner (2003) (45)
- Insulin Regulates Heregulin Binding and ErbB3 Expression in Rat Hepatocytes* (1996) (43)
- Selection of Heregulin Variants Having Higher Affinity for the ErbB3 Receptor by Monovalent Phage Display* (1998) (42)
- Catalytic effect of sulfhydryl oxidase on the formation of three-dimensional structure in chymotrypsinogen A. (1978) (40)
- A Discrete Three-amino Acid Segment (LVI) at the C-terminal End of Kinase-impaired ErbB3 Is Required for Transactivation of ErbB2* (1999) (39)
- Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose (2012) (39)
- Regulation of the acetylcholine receptor epsilon subunit gene by recombinant ARIA: an in vitro model for transynaptic gene regulation. (1995) (38)
- The biology of human epidermal growth factor receptor 2 (1999) (38)
- Development of herceptin. (2000) (31)
- Selenoprotein A of the clostridial glycine reductase complex: purification and amino acid sequence of the selenocysteine-containing peptide. (1988) (28)
- Establishment of Schwann cell lines from normal adult and embryonic rat dorsal root ganglia (1996) (28)
- Dose-response studies of recombinant humanized monoclonal antibody 2C4 in tumor xenograft models (2003) (27)
- Enhanced expression of heregulin in c‐erb B‐2 and c‐Ha‐ras transformed mouse and human mammary epithelial cells (1996) (25)
- Antitumor Effects of MEHD7945A, a Dual-Specific Antibody against EGFR and HER3, in Combination with Radiation in Lung and Head and Neck Cancers (2015) (24)
- Analysis of heregulin-induced ErbB2 phosphorylation with a high-throughput Kinase receptor activation enzyme-linked immunosorbant assay. (1996) (24)
- Resolution of sulphydryl oxidase from gamma-glutamyltransferase in bovine milk by covalent chromatography on cysteinylsuccinamidopropyl-glass. (1983) (23)
- Inhibition of HER 2 / neu ( erb B-2 ) and Mitogen-activated Protein Kinases Enhances Tamoxifen Action against HER 2-overexpressing , Tamoxifen-resistant Breast Cancer Cells 1 (2000) (21)
- Kinetic mechanism and specificity of bovine milk sulphydryl oxidase. (1984) (20)
- HER pathway gene expression analysis in a phase II study of pertuzumab + gemcitabine vs. gemcitabine + placebo in patients with platinum-resistant epithelial ovarian cancer (2008) (19)
- Simultaneous single-step purification of thiolase and NADP-dependent 3-hydroxybutyryl-CoA dehydrogenase from Clostridium kluyveri. (1984) (18)
- Structural requirements for ErbB2 transactivation. (2001) (18)
- Backbone dynamics of the EGF-like domain of heregulin-alpha. (1998) (18)
- Nonidentity of sulfhydryl oxidase and γ-glutamyltransferase in bovine milk (1981) (17)
- Purification and immunological studies of selenoprotein A of the clostridial glycine reductase complex. (1987) (16)
- Cells HER 2-overexpressing , Tamoxifen-resistant Breast Cancer Kinases Enhances Tamoxifen Action against B-2 ) and Mitogen-activated Protein erb ( neu Inhibition of HER 2 / Updated (2000) (16)
- Serological evaluation of Escherichia coli-expressed human T-cell leukemia virus type I env, gag p24, and tax proteins (1990) (15)
- Toward an Effective Targeted Chemotherapy for Multiple Myeloma (2009) (15)
- Abstract A135: T-DM1-induced thrombocytopenia results from impaired platelet production in a HER2-independent manner. (2011) (15)
- Labeling of cysteine-containing peptides with 2-nitro-5-thiobenzoic acid. (1985) (9)
- Selenium-dependent glycine reductase: differences in physicochemical properties and biological activities of selenoprotein A components isolated from Clostridium sticklandii and Clostridium purinolyticum. (1988) (8)
- 515 POSTER Trastuzumab-mertansine (T-DM1) retains all the mechanisms of action (MOA) of trastuzumab and is extremely effective in combination with docetaxel (2008) (8)
- Abstract 637: MEHD7945A, an EGFR/ErbB3 dual specific antibody, overcomes acquired resistance to EGFR inhibitors in head and neck and lung tumors (2011) (7)
- Effects of in vivo heregulin beta1 treatment in wild-type and ErbB gene-targeted mice depend on receptor levels and pregnancy. (2001) (7)
- Abstract 5607: Dual targeting of HER2: Enhanced antitumor efficacy of trastuzumab-DM1 combined with pertuzumab (2010) (7)
- Characterization of selenomethionine in proteins. (1984) (6)
- HER2-Targeted Polyinosine/Polycytosine Therapy Inhibits Tumor Growth and Modulates the Tumor Immune Microenvironment (2016) (6)
- AN IMPROVED METHOD FOR QUANTITATION OF SULFHYDRYL CONCENTRATION IN TURBID SAMPLES (1980) (5)
- Pari passu dimers of dimers (2012) (5)
- Abstract 1207: Preclinical development of 2nd generation HER2-directed antibody-drug conjugates (2016) (4)
- Trastuzumab-MC-vc-PAB-MMAF: The effects of the Drug:Antibody Ratio (DAR) on efficacy, toxicity and pharmacokinetics. (2007) (4)
- Assay of enzyme-catalyzed oxygen-dependent disulfide bond formation. (1987) (3)
- Selenomethionine-containing thiolase and 3-hydroxybutyryl-CoA dehydrogenase from Clostridium kluyveri. (1985) (2)
- Differential expression of microRNAs induced by trastuzumab emtansine (T-DM1) during megakaryocytopoiesis. (2013) (2)
- 5020 Pharmacokinetics (PK), safety, and efficacy of trastuzumab (T)-DM1, a HER2 antibody-drug conjugate (ADC), in patients with HER2+ metastatic breast cancer (MBC): phase I and phase II trial results (2009) (2)
- ErbB2/Her2 ectodomain shedding is regulated by a membrane-associated metalloprotease (2005) (2)
- TYROSINE PHOSPHATE AND TYROSINE SULFATE IN PROTEINS (1983) (2)
- Downregulation of HER3: A potential surrogate for activation of HER2 through heterodimerization may predict clinical benefit in ovarian cancer from pertuzumab, a HER dimerization inhibiting antibody (2007) (2)
- Identification of head and neck cancers (SCCHN) that may respond to dual inhibition of EGFR and HER3 signaling. (2012) (2)
- Neuregulin receptor-mediated gene transfer by human epidermal growth factor receptor 2-targeted antibodies and neuregulin-1 (1999) (2)
- Abstract 2721: MEHD7945A, dual specific antibody against EGFR and HER3, augments radiation response in head and neck squamous cell carcinoma (2012) (2)
- An open-and-shut case (2003) (2)
- Abstract 1212: The dual action antibody MEHD7945A targeting EGFR and HER3 enhances chemotherapy induced cytotoxicity in vitro and in vivo (2012) (1)
- Improved antitumor therapy by dual targeting of estrogen and growth factor receptor signaling in human breast cancer cells. (2006) (1)
- Treatment of HER 2-Amplified Breast Cancer Efficacy of Afucosylated Trastuzumab in the In vivo (2010) (1)
- Nonidentity of sulfhydryl oxidase and gama-glutamyltransferase in bovine milk. (1981) (1)
- HER2 Overexpression Induces Membrane Deformation that Increases Cell Motility (2014) (1)
- Evolution of the MDA-MB-175 breast cancer cell line from a low to a high HER2 expressing tumor line (2005) (1)
- ThioMabs: improving safety abd retaining efficacy of antibody drug conjugates (2007) (1)
- Panel Discussion II (1987) (0)
- 208 POSTER Pharmacokinetic (PK), pharmacodynamic (PD) modeling and simulation analysis of PRO132365, a HER2 antibody-drug conjugte (2006) (0)
- Resolution ofsulphydryl oxidase fromy-glutamyltransf erase inbovine milk bycovalent chromatography on cysteinylsuccinamidopropyl-glass (1983) (0)
- Use of heregulin as epithelzellenwachstumsfaktor (1999) (0)
- Treatment of cancer with the recombinant humanized anti-ErbB2 antibody 2C4 (rhuMAb 2C4) (2003) (0)
- Method for treating prostate cancer in a human, article of manufacture and the use of an antibody which binds ErbB2 (2000) (0)
- Animal Model Effects of in Vivo Heregulin 1 Treatment in Wild- Type and ErbB Gene-Targeted Mice Depend on Receptor Levels and Pregnancy (2001) (0)
- An enzymatic approach to flavor modification. (1980) (0)
- Engineering novel ThioFab/Mabs for site specific conjugation of cytotoxic drugs (2006) (0)
- 5002 ORAL Results from a Phase II randomized, placebo-controlled, double-blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer (2007) (0)
- of Multivalent Antibodies Design, Construction, and In Vitro Analyses (2017) (0)
- Use of heterogublina like growth factor epithelial cells. (1999) (0)
- Predictive Biomarkers and Personalized Medicine Analysis of Fc g Receptor IIIa and IIa Polymorphisms : Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients (2012) (0)
- Tamoxifen Action against HER2-overexpressing, Tamoxifen-resistant Breast Cancer Cells 1 (2000) (0)
- Epidermal Growth Factor Receptor tyrosine kinase domain with 4-anilinoquinazoline inhibitor erlotinib (2002) (0)
- The use of ErbB4 specific antagonists for the treatment of stenosis (2001) (0)
- Cytotoxic Drug Conjugate − Trastuzumab-DM 1 , an Antibody Targeting HER 2-Positive Breast Cancer with Updated (2008) (0)
- The Nature of Constitutive Activation of HER2 at the Single Molecule Level (2012) (0)
- MExpression in Node-negative Breast Cancer : Direct Tissue Quantitation by Computerized Image Analysis and Association of Overexpression with Increased Risk of Recurrent Disease 1 (2006) (0)
- Tyrosine Kinase Domain from Epidermal Growth Factor Receptor (2002) (0)
- Combined treatment of tumors expressing her (2006) (0)
- Use of heregulin as a epitelcellevækstfaktor (1999) (0)
- Beyond Cetuximab for Head and Neck Cancer: Dual Target Antibody Blockade of EGFR and HER3 Enhances Radiosensitivity and Overcomes Acquired Resistance to EGFR Inhibitors (2011) (0)
- Methods of treatment using conjugates of anti-ErbB-maytansinoid (2000) (0)
- Membrane Deformation by HER2 Overexpression Disrupts Epithelial Integrity (2015) (0)
- Abstract 3330: HER2 overexpression induces membrane deformation that increases cell motility (2014) (0)
- Treatment methods using anti-ErbB-maitansinoid antibody conjugates (2000) (0)
- Management of prostate cancer with anti-ErbB2 antibodies. (2000) (0)
- Abstract 4396: Conjugation site modulates the stability and biological activity of antibody drug conjugates (2010) (0)
- Cancer treatment with the antibody directed against ErbB2 rhuMAb 2C4 (2003) (0)
- Combinations of a drug conjugate-anti-HER2 and docetaxel (2009) (0)
- Treatment of the cancer with the antibody directed against ErbB2 rhuMAb 2C4. (2003) (0)
- 246 New platforms of immunoconjugates (2010) (0)
- Combinations of an antibody-drug conjugate of anti-HER2 and chemotherapeutic agents, and methods of use (2009) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Mark X. Sliwkowski?
Mark X. Sliwkowski is affiliated with the following schools: